A new prognostic index, defined as the cancer-inflammation prognostic index (CIPI), based on CEA and NLR, was recently introduced as a promising novel prognostic marker for metastatic CRC patients treated with regorafenib [26,27]. This evidence concerns the gene CEACAM5 and cancer.